Long-Term Follow-Up Of Exceptional Responders On The Phase Ii Trial Of Weekly Bortezomib And Rituximab In Untreated And Relapsed Patients With Waldenstrom'S Macroglobulinemia.
JOURNAL OF CLINICAL ONCOLOGY(2016)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要